Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2008

View Archived Issues

Clinical data on besifloxacin in bacterial conjunctivitis reported

Neuronal nicotinic receptor ligands profiled at AstraZeneca

Novel analgesic agents imparted in recent Glenmark, Merck and GSK patents

New therapeutic agents for neurological disorders reported by Taisho and Novartis

Recent Kowa and AstraZeneca patents impart new treatments for respiratory and allergic disorders

Novartis provides update of recent pipeline activity

First-in-human results of NGF enhancer KRX-0501 for the treatment of neurological disorders

PF-00868554 active, well tolerated in double-blind HCV study

Advitech and Laboratoires Urgo sign collaboration agreement in wound healing

HCV candidate BMS-790052 well tolerated in proof-of-concept study

PRT-201 shows potential to improve arteriovenous fistula surgery results

Positive phase III results reported for JZP-6 in fibromyalgia

FDA accepts Vanda's resubmission of NDA for iloperidone

Arpida provides update on iclaprim's regulatory pathway

FDA grants approval to SuperGen to initiate clinical trials of Pim inhibitor SGI-1776

Synta initiates treatment of patients in phase I/II trial of elesclomol in prostate cancer

Biovitrum reports positive results from clinical trial of Sym-001 in HDN

EMEA advises Santhera of negative opinion for idebenone MAA in Friedreich's ataxia

Enrollment suspended following DMC review of phase III MONET trial of motesanib

Aastrom treats first patient in U.S. phase II IMPACT-DCM trial

Takeda submits European MAA for once-daily Competact formulation

Nplate receives positive CHMP opinion for MAA in Europe

RoActemra receives positive opinion in Europe for rheumatoid arthritis

Rasilez HCT receives positive CHMP opinion for treatment of high blood pressure

FDA approves tapentadol immediate-release tablets for acute pain

Invitrogen and Applied Biosystems complete merger

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...